<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593227</url>
  </required_header>
  <id_info>
    <org_study_id>FRV-002</org_study_id>
    <nct_id>NCT02593227</nct_id>
  </id_info>
  <brief_title>Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer</brief_title>
  <official_title>A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (&lt; 10%) ER/PR Nuclear Staining</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tapimmune Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tapimmune Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate
      Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or
      without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant
      or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple negative breast cancers (TNBCs) occur in approximately 20-25% of all patients with
      breast cancer and are associated with a poor prognosis. Patients with TNBCs derive no
      benefit from targeted therapies. Excluding those patients who demonstrate a pathologic
      complete response following neoadjuvant chemotherapy, which is a minor fraction (i.e. 15%),
      overall survival is only 45% at 7 years.

      Following standard of care, there are windows of opportunity to further and safely treat
      patients to prevent recurrence. Stimulating the immune system to produce T cells immunity
      specific for tumor antigens may significantly delay recurrence and cure patients.

      The proposed vaccine is intended to induce T cells to survey for the reemergence of TNBCs
      and to prevent recurrence in the adjuvant setting. The vaccine strategy is antigen-specific
      and targets the Folate Receptor Alpha (FRα). FRα is an ideal target because of its limited
      expression in the healthy tissues and it high expression in 86% of TNBCs. Studies have shown
      that it is a biologically important marker that is associated with poorer clinical outcome
      and is retained in metastatic lesions.

      The FRα vaccine include a pool of 5 peptides that are immunogenic epitopes and safely
      generate tissue-surveying CD4 T cell immune responses in patients tested in a recently
      completed phase I clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>3 years</time_frame>
    <description>Emergence of B and T cell immunity targeting the folate receptor alpha</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Folate receptor alpha expression</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine FRα expression status of primary tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>RFS in relation to FR specific immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (treatment emergent adverse events and injection site reactions)</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of treatment emergent adverse events and injection site reactions</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Low dose FRα vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose FRα vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose FRα vaccine + cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose FRα vaccine + cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low dose FRα vaccine</intervention_name>
    <description>165ug per peptide ID injection</description>
    <arm_group_label>Low dose FRα vaccine</arm_group_label>
    <arm_group_label>Low dose FRα vaccine + cyclophosphamide</arm_group_label>
    <other_name>TPIV200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>IV infusion over 1 hour</description>
    <arm_group_label>Low dose FRα vaccine + cyclophosphamide</arm_group_label>
    <arm_group_label>High dose FRα vaccine + cyclophosphamide</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High dose FRα vaccine</intervention_name>
    <description>500ug per peptide ID injection</description>
    <arm_group_label>High dose FRα vaccine</arm_group_label>
    <arm_group_label>High dose FRα vaccine + cyclophosphamide</arm_group_label>
    <other_name>TPIV200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient, Age 18 years or older;

          -  Written informed consent;

          -  Negative for ER, PR and negative for Her2-neu (0 or 1+ on immunohistochemistry and/or
             normal gene copy number by fluorescence in-situ hybridization);

          -  Completed surgery and radio/chemotherapy in adjuvant or neo-adjuvant setting &lt;360
             days prior to first vaccination.

          -  Completed last cycle of chemotherapy or radiation &gt; 60 days prior to first
             vaccination

          -  Unilateral or bilateral primary carcinoma of the breast with tumor Stage II-III
             according to AJCC 7th edition, and one of the following:

               1. For patient treated in the neoadjuvant setting: Histologically detectable tumor
                  residuals (excludes ypT0/is ypN0), M0 and no evidence of gross tumor or gross
                  residual adenopathy.

               2. For patients treated in the adjuvant setting: pN2-3 and M0. No evidence of gross
                  tumor or gross residual adenopathy

          -  Adequate Blood, renal and hepatic function, as determined within 28 days from
             enrollment:

        Exclusion Criteria:

          -  Clinical evidence of distant metastases per practice guidelines for breast cancer;

          -  Inflammatory breast cancer or tumor with deep adherence or cutaneous invasion;

          -  Known hypersensitivity reaction to the GM-CSF adjuvant; Any known contra-indication
             to GM-CSF or Cyclophosphamide treatment;

          -  Pregnant or lactating patients.

          -  History of auto-immune diseases;

          -  Other uncontrolled illness or medical condition , such as active infection,
             symptomatic heart failure, unstable angina pectoris, myocardial infarction or stroke
             within last 6 months, psychiatric illness that may limit compliance with study
             requirement or interfere with the understanding and giving of informed consent;

          -  Prior active secondary malignancy &lt; 5 years prior to consent (except non-melanomatous
             skin cancer or carcinoma in situ of the uterine cervix) or currently receiving other
             specific treatment for this cancer (including monoclonal antibody or pathway
             inhibitor);

          -  Completed treatment with systemic corticosteroid or immune-modulators &gt; 30 days prior
             to registration;

          -  Planned treatment with other experimental drugs or any other anti-cancer therapy;

          -  Immunocompromised patients including patients with known HIV infection;

          -  Currently receiving thyroid replacement therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Kenney, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tapimmune Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Kenney, MD</last_name>
    <phone>206.946.8012</phone>
    <email>rkenney@tapimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald Garrett</last_name>
    <email>ggarrett@tapimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Carney, RN</last_name>
      <phone>813-745-1807</phone>
      <email>dawn.carney@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Heather Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Hepler</last_name>
      <phone>913-945-7552</phone>
      <email>khepler@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Priyanka Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Tait, RN, BSN</last_name>
      <phone>410-328-3546</phone>
      <email>ntait@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Tkaczuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Weise, DO</last_name>
      <phone>800-527-6266</phone>
      <email>weisea@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Amy Weise, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAmerica Division,Inc</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Kuhn, BSN</last_name>
      <phone>913-967-9328</phone>
      <email>teresa.kuhn@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Stephanie Graff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiby George, CRC</last_name>
      <phone>212-824-7822</phone>
      <email>fiby.george@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Tiersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, Einstein Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Calderon</last_name>
      <phone>718-405-8535</phone>
      <email>vcaldero@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Sparano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Given</last_name>
      <phone>513-751-2273</phone>
      <email>ngiven@ohcare.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Ward, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central contact:askSARAH</last_name>
      <phone>877-691-7274</phone>
      <email>askSARAH@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi McIntyre, MD</last_name>
      <phone>214-739-4175</phone>
    </contact>
    <investigator>
      <last_name>Kristi McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tapimmune.com</url>
    <description>Corporate website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>October 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
